ethyl 4-(3-aminopyridin-2-ylamino)piperidine-1-carboxylate | 107618-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-(3-aminopyridin-2-ylamino)piperidine-1-carboxylate
• 英文别名: Ethyl 4-[(3-amino-2-pyridinyl)amino]-1-piperidinecarboxylate；ethyl 4-[(3-aminopyridin-2-yl)amino]piperidine-1-carboxylate
• CAS: 107618-22-4
• 化学式: C₁₃H₂₀N₄O₂
• 分子量: 264.327
• InChiKey: NDSRPPSGFLJQOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  80.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 4-(3-aminopyridin-2-ylamino)piperidine-1-carboxylate 在 sodium hydroxide 、 potassium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 14.0h， 生成 3-[1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)piperidin-4-yl]-1H-imidazo[4,5-b]pyridin-2-one
  参考文献：
  名称：

  Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimidazolone derivatives

  摘要：

  A series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimid azolones with various substituents in both aromatic rings have been synthesized and tested for neuroleptic activity (antiapomorphine effects and [3H]spiroperidol binding) as well as extrapyramidal effects (cataleptogenic effect). A strong dependence of activity on the 5-substituent in the benzimidazolone moiety could be demonstrated. Some compounds show a large split between the desired antiapomorphine and the undesired extrapyramidal effect. From these, 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]-5-chlor obenzimidazol-2-one hydrochloride (HR 723), 12, has been selected for further preclinical and toxicological profiling.

  DOI：

  10.1021/jm00388a012
• 作为产物：
  描述：

  2-氯-3-硝基吡啶 在 镍 氢气 、 sodium carbonate 、 potassium iodide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 29.0h， 生成 ethyl 4-(3-aminopyridin-2-ylamino)piperidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimidazolone derivatives

  摘要：

  A series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimid azolones with various substituents in both aromatic rings have been synthesized and tested for neuroleptic activity (antiapomorphine effects and [3H]spiroperidol binding) as well as extrapyramidal effects (cataleptogenic effect). A strong dependence of activity on the 5-substituent in the benzimidazolone moiety could be demonstrated. Some compounds show a large split between the desired antiapomorphine and the undesired extrapyramidal effect. From these, 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]-5-chlor obenzimidazol-2-one hydrochloride (HR 723), 12, has been selected for further preclinical and toxicological profiling.

  DOI：

  10.1021/jm00388a012

文献信息

• 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
  申请人：de Lera Ruiz Manuel

  公开号：US20070066644A1

  公开（公告）日：2007-03-22

  The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.

  本发明公开了化合物I的结构以及其药学上可接受的盐和溶剂化合物。该发明还涉及包括化合物I的药物组合物，并且其在治疗肥胖症、代谢综合征、糖尿病、肝脂肪病或非酒精性脂肪肝病中的用途。该发明还涉及将化合物I与其他治疗剂的组合物用于治疗肥胖症、代谢综合征、糖尿病、肝脂肪病或非酒精性脂肪肝病。
• Imidazopyridine derivatives as PI3K inhibitors
  申请人：Almirall, S.A.

  公开号：EP2518071A1

  公开（公告）日：2012-10-31

  New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

  新的咪唑吡啶衍生物具有化学结构式(I)，公开了它们的制备方法，包括它们的药物组合物以及它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的用途。
• [EN] IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE PI3K
  申请人：ALMIRALL SA

  公开号：WO2012146667A1

  公开（公告）日：2012-11-01

  New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

  揭示了具有化学结构公式（I）的新咪唑吡啶衍生物；以及它们的制备方法，包含它们的药物组合物和它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的用途。
• [EN] BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2008108958A8

  公开（公告）日：2009-08-13
• Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: Optimization of the 4-substituted piperidine
  作者：Christopher S. Burgey、Craig A. Stump、Diem N. Nguyen、James Z. Deng、Amy G. Quigley、Beth R. Norton、Ian M. Bell、Scott D. Mosser、Christopher A. Salvatore、Ruth Z. Rutledge、Stefanie A. Kane、Kenneth S. Koblan、Joseph P. Vacca、Samuel L. Graham、Theresa M. Williams

  DOI：10.1016/j.bmcl.2006.07.044

  日期：2006.10

  In our continuing effort to identify CGRP receptor antagonists for the acute treatment of migraine, we have undertaken a study to evaluate alternative 4-substituted piperidines to the lead dihydroquinazolinone 1. In this regard, we have identified the piperidinyl-azabenzimidazolone and phenylimidazolinone structures which, when incorporated into the benzodiazepine core, afford potent CGRP receptor antagonists (e.g., 18 and 29). These studies produced a potent analog (18) which overcomes the instability issues associated with the lead structure 1. A general pharmacophore for the 4-substituted piperidine component of these CGRP receptor antagonists is also presented. (c) 2006 Elsevier Ltd. All rights reserved.